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Abstract: 
Surgery to implant a total hip replacement (THR) is very successful in reducing pain 
and restoring function. This procedure has become more prevalent, and projections 
estimate further increases in demand. However, complications can arise, and current 
diagnostic techniques often fail to expose underlying issues before they result in a 
catastrophic failure that requires revision surgery. An instrumented implant, with 
embedded sensors capable of real time condition monitoring, would be an attractive 
proposition to incorporate within a THR. Continued advances in the performance and 
miniaturisation of electronic components, embedded systems, sensing and wireless 
communications have given the tools and resources medical device manufacturers 
need to innovate in the field of implantable medical devices. Smart implants are 
already being widely used in healthcare including pacemakers, cochlear implants, 
glucose monitors and insulin pumps however, a widely used smart THR has not yet 
been realised. Since the implantation of the first instrumented hip implant in the 1960s 
there have been several in-vitro studies monitoring levels of implant loosening. 
Additionally, significant research has been conducted using instrumented THRs to 
perform in-vivo measurement of biomechanical metrics, including force and moments. 
To date less than 100 patients have successfully received an instrumented implant. 
The results of these studies have aided researchers, designers and surgeons in wider 
research projects, however, the motivation behind the work was to provide discrete 
biomechanical data sets and not provide real-time condition monitoring of an implants 
performance or highlight early indications for revision surgery. If in-vivo sensing within 







































































a THR is to be achieved and adopted in regular clinical practice then the following 
challenges need to be addressed: choice of the sensing method, biocompatibility and 
integration within the implant, power supply, communication, and regulatory 
considerations. 
  








































































Total hip replacement (THR) surgery is a successful intervention and relives pain and 
restores function [1]. National joint registries [2]–[4] have all shown consistent increase 
in the number of THR surgeries performed annually and projections are estimate 
further growth in the demand for both primary and revision procedures [5], [6]. 
Furthermore, patient expectations are changing as younger patients are undergoing 
THR and increasingly demand return to recreational activities [7]. Despite the success 
of THR surgery, complications can still arise, and current diagnostic techniques often 
take too long to expose underlying issues before they result in catastrophic failure 
which may result in revision surgery. Revisions are undesirable because of increased 
surgery time, complication rates and expense. Equally, unnecessary clinical reviews 
of well–functioning THRs are routinely carried out because there is no alternative to 
assess on-going function. The use of in-vivo sensing capable of real time condition 
monitoring of the implant’s performance, occurrence of adverse events and patient 
health metrics offers a potential solution. Research in this area was first explored in 
the 1960’s, however, despite almost 60 years of continued innovation, there has not 
been widespread adoption in orthopaedics. Recent advancements in materials, 
manufacturing and electronics may provide new potential innovations in the field of in-
vivo sensing and smart implants thus making it an opportune moment to conduct a 
review on past systems and applicable technology. 
 
Why is it desirable to have telemetry in an implanted medical device? 
An implanted medical device (IMD) with sensing capabilities and telemetric link could 
provide a means of continuous monitoring as oppose to traditional episodic monitoring 
[8]. This would enable clinicians to track the post-operative recovery process, better 
guide personalised postoperative care [9], [10] and empowers patients with the ability 
to review and manage the health of their implant. Additionally, the system could 
provide alerts on the occurrence of adverse events to give an early indication of the 
need for further investigation, or modification in activities. 
Increased availability of cheaper, smaller and more powerful integrated circuits 
and semiconductors has led to huge technological advances in electronics, sensing 
and communications. These advances and increased adoption of technology in 







































































healthcare has meant that smart IMDs are becoming a reality and are commonly used 
across healthcare. For example, the Freestyle Libre continuous glucose monitor 
(Abbott, Ill, US) offers an alternative to traditional finger prick blood glucose tests. The 
Freestyle Libre offers a pain free method for continuously measuring blood glucose 
levels and information on the direction blood glucose levels are trending. This 
demonstrates an example of how the advent of technology has improved both the 
convenience and quality of the care. 
The data gathered by an instrumented implant could inform the healthcare 
professional during their diagnostic decisions. In the case of a THR this data could 
include (for example) metrics on the performance of the implant or activity of an 
individual patient such as daily steps, range of motion, and condition of the bone-
implant bond or wear of the bearing surfaces. Furthermore, this data would also be 
valuable to researchers to gain a better understanding of the overall use and 
performance of THRs across a patient population. Ultimately this research could be 
used to refine the design and surgical placement of existing implants to give enhanced 
performance and increased longevity. If these improvements were achieved, they 
would be of benefit patients and clinicians; and also providers (healthcare systems) 
and financiers (governments and insurance companies).  
 
How do hip implants fail? 
The common indications and percentage occurrence for primary revision following 
primary THR surgery (that occurred in England, Wales, Northern Island, the Isle of 
Man and the States of Guernsey from 1st April 2003 to 1st March 2020 [2]) are 
summarised in Figure 1. In the short term (less than one year after primary hip 
replacement), the most common indications for revision (as measured by failures per 
1000 prosthesis-years) were dislocation/subluxation (2.50), infection (1.92), peri-
prosthetic fracture (1.71), aseptic loosening (1.03), reaction to particulate debris (0.77) 
and malalignment (0.73). Clearly pain cannot be detected by means of an 
instrumented implant however there is scope for the other listed indications to be 
detected in-vivo. 
 







































































Figure 1 – Common indications for primary revision following primary revision surgery as reported by 
the 17th Annual Report of the National Joint Registry [2]. *Other indications of note include 
malalignment, implant wear and implant fracture. 
 
The indications for revision demonstrate different modes in which an implant 
can fail, all may be linked to patient reported pain.  This can make an initial diagnosis 
through clinical observations a challenge. An instrumented hip implant could give 
quantitative data demonstrating an adverse event providing an early indication for the 
need for clinical review. This could reduce the diagnostic pathway providing a quicker 
diagnosis thus reducing the impact of time sensitive conditions [8]. 
This review will look at the current state of the art of instrumented hip implants 
focusing on their capability to perform in-vivo sensing and translation into routine 
clinical practice. Following this the challenges that will need to be overcome for in-vivo 
sensing systems to be viable will be considered. These are as follows: choice of sensor 
(including author recommendations on potential sensing applications for use within a 







































































THR), biocompatibility and integration within the implant, power, communication, and 
regulatory considerations. 
  







































































2. Review: Instrumented hip implants current state of the art 
The review’s findings are reported in sections on related to the indication for revision 
or main phenomena that the study was looking to detect or monitor; (i.e. biomechanics 
and aseptic loosening).  
 
2.1 Biomechanics 
In terms of instrumented hip implants, most of the focus has been on studying the 
biomechanics of THRs and function in an in-vivo environment. Strain gauges, 
piezoelectric transducers and temperature sensors have been used to measure 
forces, pressures, moments and temperatures in-vivo. The data collected in these 
studies has been important in validating computational and cadaveric models, and 
inform designers and surgeons thus improving implant design and surgical technique. 
 
2.1.1 Early Work on Measuring Hip Joint Force In-Vivo 
The first use of sensors in an instrumented implant, for in-vivo use, was that of Rydell 
et al [11] who positioned strain gauges within the neck of the femoral prosthesis. The 
prosthesis was implanted successfully in two patients successfully and six months 
later a second surgery passed lead wires out of the skin to allow for data collection. 
After a week these lead wires were designed to be cut free by a sharp edge at the 
junction with the prosthesis however this method failed, and a separate operation had 
of be conducted to remove the leads. Results (in terms of measured load) were 
recorded from two patients were collected (Table 1). 
Convenience, improved patient comfort and reduced risk of infection led to the 
use of wireless connections. An approach, first described by English and Kilvington 
[12] and later in Kilvington and Goodman [13], was to use battery power and a FM 
transmitter chip (Sandev SNlO2F) operating at 102.3 MHz. Their implant consisted of 
a sealed piston with four strain gauges thus forming a load cell capable of measuring 
the axial compressive load transmitted through the neck of the femoral component. A 
cable was passed out of the implant stem and led to an implanted Perspex box where 
the transmitter and accompanying electronics were housed, the cable and box were 
encapsulated within silicone rubber. The system had an operational battery life of 







































































approx. 70 hours and with the use of sub miniature magnet controlled reed switches, 
recordings could be made up to 43 days post-op [12]. Results (load from walking and 
one legged stance) from a single patient were collected (Table 1).  
Other early work measured contact pressures at the joint surface, Carlson et al 
[14] developed a prototype prosthesis to measure the magnitude and distribution of 
pressure generated over the inner surface of a natural human hip socket. The implant 
featured 14 pressure transducers covering the outer surface of the femoral head, and 
a 16-channel telemetry system located within the femoral head. The power and data 
transfer induction coil were located at the distal end of the implant, allowing the implant 
to be powered by an external power coil. A similar approach was adopted by Otake et 
al [15] who developed a modified femoral head with eight sub-miniature pressure 
sensors embedded over the surface and covered with a spherical ABS plastic surface 
to reduce friction. The device was limited in that it was only intended to measure 
intraoperative pressures at the bearing contact surfaces. 
 
2.1.2 3D Force Measurements Acting on the Femoral Stem 
In 1979 Georg Bergmann developed a new method for measuring force distributed 
over a femoral head termed the matrix method [16]. The method required only one 
sensor for each load component and so meant that 3D force measurements could be 
made on the femoral head with the use of only three strain gauges positioned within 
the femoral neck (on the inner surface). Bergmann then developed his own 
instrumented hip implant that he initially tested in sheep [17]. A functional 
telemeterised hip for in-vivo human use was first described and implanted in 1988 [18]. 
The implant, (Figure 2a), included three semiconductor strain gauges positioned on 
the inner wall of the hollow neck. The remaining electronics, including the power coil 
and RF transmitter, were placed on both sides of a 15mm X 7mm wide substrate and 
housed in an 8mm X 25mm cylinder. The top plate of the cylinder had two lead 
throughs that connect to the RF transmitter antenna which was fitted into the cavity of 
a ceramic head [19].  Two patients received the instrumented hips, firstly in 1988 a 
bilateral procedure (both hips) was performed on an 82 year-old male with height 
168cm and bodyweight (BW) 650N, and then in 1990 in the right hip of a 69 year-old 






































































female of height 160cm and BW 470N. Results recorded (peak loads in walking and 
stumbling) from the two patients are shown in Table 1.  
 In the 1990s Bergmann’s group developed a further endoprosthesis which 
measured the force components experienced by the head and also the temperature 
distribution across the full length of the femoral stem [20]. The implant, (Figure 2b) 
was based on the hollow shaft hip endoprosthesis CENOS (ARTOS, Berlin, Germany) 
and featured three semiconductor strain gauges and two temperature sensors (TS1 & 
TS2 Figure 2b) glued to the inner surface of the hollow neck along with an additional 
six temperature sensors (TS3 - TS8 Figure 2b) positioned along the shaft of the stem. 
The power coil and two telemetry units were positioned within the hollow shaft, which 
was sealed by a top plate. The top plate was welded to the top of the implant neck, 
and featured two lead throughs that allowed connection to the antenna that occupied 
the cavity of the ceramic head, [20] similar to the previous endoprosthesis [19]. 
 In 2001 Bergmann and colleagues published the results of two studies 
conducted using these new endoprosthesis [21], [22]. Firstly, contact forces were 
reported from four patients’, age range 51 – 76 years and BW range of 702N – 980N. 
Hip contact force results collected from these four patients are shown in Table 1. In 
the second study temperature measurements were made in seven patients’, age 
range 51 – 82 years. Peak temperature of implants with a polyethylene liner was 
measured at 43.18°C after an hour of walking and was observed in sensor TS1 which 
was positioned at the top of the neck [22], (Figure 2b). 







































































Figure 2a – Cross section of Bergmann’s first hip endoprosthesis for force measurements [18]. Figure 
2b – Bergmann’s hollow shaft smart prosthesis capable of force measurement and temperature 
measurement along the full length of the stem [22].  
 The third iteration of Bergmann’s instrumented hip prosthesis [23] was based 
on a “Cementless Tapered Wedge” (CTW) prosthesis (Merete Medical GmbH, Berlin, 
Germany). This allowed for the measurement of forces and moments acting in the 
joint. Three custom-made twin semiconductor strain gauges were positioned inside 
the hollow neck along with a nine-channel telemetry transmitter and an internal 
induction coil. A cut-out model of the prosthesis is shown in Figure 3a. The prosthesis 
had a transmission range of 50cm [23]. In 2013 Damm and colleagues [24] reported 
in-vivo friction measurements using Bergmann’s modified CTW prosthesis. Results at 
3 months post-op from eight subjects, age range 50 – 69 years and BW range of 754N 
– 899N and are shown in Table 1.  
  







































































Table 1 – Summary of studies reporting in-vivo loads measured through hip joint  
Study Method Patients Stance/Activity Measured load 
through joint 







2 One-legged stance 2.3X (peak patient 1) 
2.9X (peak patient 2) 
Walking 1.3m/s 
(patient 1) & 1.4m/s 
(patient 2) 
1.8X (peak patient 1) 







1 One-legged stance  2.8X (12 days post-
op) & 2.2X (40 days 
post-op) 
Walking  2.0X (12 days post-








1 One-legged stance 
(31 days post-op) 
2.1X  
Walking  2.6X to 2.8X (range) 







2 One-legged stance 
(23 days post-op) 
2.1X to 2.8X (range) 







2 Walking 0.3m/s 
(patient 1) & 1.4m/s 
(patient 2) 
2.8X (peak patient 1) 
& 4.8X (peak patient 
2) 
Stumbling 7.2X (peak patient 1) 








4 One-legged stance  2.3X (mean from 4 
patients) 
Walking (1.1m/s) 2.4X (mean from 4 
patients) 






8 Walking (3 months 
post-op) 
2.5X (mean from 8 
patients) 
 
Bergmann et al [28] also developed a further prosthesis based on the CTW 
design solely for in-vivo temperature measurements. This had a 6.2mm diameter X 
50mm long bore in the neck for the thermistor and accompanying electronics, (Figure 
3b). Bergmann’s previous implants had all featured internal power coils and an 
external niobium antenna. The new prosthesis however, had a combined power and 
data coil positioned within a hermetically sealed chamber instead of being positioned 
in the recess of the femoral head and encapsulated in silicone. The justification being 
that the plastic encapsulation of electronics should only be used for non-permanent 







































































implants [28]. To date no study has been reported from this prosthesis however, 
Bergmann et al. [28] state that a clinical study on temperature rise in hip implants was 
planned in 100 patients. 
  
Figure 3a – Bergmann’s first CTW implant with three twin semiconductor strain gauges, internal 
power coils and an external niobium antenna [23]. Figure 3b – The latest of Bergmann’s smart 
implants and the first to feature a combined power and data transfer coil [28].  
  







































































2.2 Implant Loosening 
Aseptic loosening is failure of the implant – bone bond in the absence of infection. It 
is the most common reason for orthopaedic implant revision. Aseptic loosening can 
cause pain and if it is diagnosed too late, can lead to a destruction of bone stock which 
can create issues when implanting a new revision implant [29]. The initiation and 
progression of aseptic loosening is multifactorial, this includes: resultant adverse 
biological reactions to cement, polyethylene, metal or ceramic particles, micromotion 
at the interface, stress shielding, high fluid pressure, endotoxin or individual and 
genetic variations [30].  
 
2.2.1 Vibration Analysis 
Vibration analysis (VA) relies on measuring the ambient vibrations and frequencies of 
a system or the vibration response following a mechanical excitation from an external 
source e.g. a shaker. A structural change or degradation within the system, for 
example an imbalance, worn and broken components or torque variations, will give 
rise to distinct features in the output signals. An abnormal vibration response can be 
more easily identified if an original or typical vibration response is known [31]. The 
frequency response of a linear system will show the excitation (input) oscillating at the 
same frequency as the output. Whereas the output of a nonlinear system will contain 
multiple harmonics. In the case of a THR, a well-fixed prosthesis can be considered 
as a linear system whereas an unstable or loose implant will behave like a nonlinear 
system, Figure 4.  








































































Figure 4 – Conceptual diagram of vibration analysis being performed on a femur and implanted stem. 
The output waveform of a well-fixed implant will match the sinusoidal nature of the input excitation 
and frequency analysis will reveal one major frequency. Conversely a loose implant will have a 
distorted output waveform and multiple harmonics will be present [32]. 
Chung et al [33] first suggested the use of VA as a diagnostic technique to 
assess THR fixation. They described the technique as safe and non-invasive because 
only a small mechanical excitation was required; that the method could be used on 
pre-existing implant designs and previously implanted prostheses and allow for the 
real time monitoring of levels of osseointegration. The in-vitro experimental setup 
included a mechanical shaker applying an excitation to the implant–bone system and 
accelerometer(s) attached to the bone, measuring the vibration response. Several 
studies report similar findings to Chung et al [33] using a femoral stem implanted in a 
femur [32], [34], [35], acetabular cup implanted in a Sawbone block [36] and complete 
THR system implanted in a Sawbone femur and pelvis [37]. Results demonstrate that 
an implant–bone interface with a loosened implant, gave a distorted output waveform, 
increased numbers of resonance peaks and a reduction in the magnitude of the 
fundamental frequency.  
Rosenstein et al [32] and Georgiou and Cunningham [38] further developed this 
concept by conducting in-vivo trials using VA to detect THR loosening in-vivo. In both 
studies, a single accelerometer was positioned over the greater trochanter and a 






































































vibrator applied excitation to the lateral epicondyle of the femur. Rosenstein et al found 
that in five patients where the VA test was positive for loosening, it was also observed 
in revision surgery. Additionally, Georgiou and Cunningham reported their VA method 
had a sensitivity of 80% and a specificity of 89%, and when compared to the standard 
radiographic method was 20% more sensitive and able to diagnose 13% more 
patients. There were however, limitations in the in-vivo method; firstly, the technique 
is unsuitable for patients who could not lie on their side or who experience pain and 
discomfort induced by the vibrator, in Georgiou and Cunningham’s study this 
accounted for 10% of the patients. Secondly, although the authors took care to position 
the sensor and shaker with “good bony contact” variations in patient soft tissue can 
greatly affect the propagation of the vibrations to the body’s surface and so affect the 
diagnostic capabilities [39].  
Using an implant with telemetry presents an alternative method that would allow 
for ongoing VA assessment of the THR component loosening. Puers et al [40] propose 
a concept that included a capacitive accelerometer sealed in a titanium can and placed 
into a recess made in the femoral head (Figure 5). The inductive power and data coils 
were fed through the lid of the titanium can and coil around the superior portion of the 
neck stem. Puers et al. [40] state that having the sensing system within the implant 
will provide far better results when compared to previous VA methods. One limitation 
of this integration method is that the required recess incurs significant modification to 
the femoral head which would affect the bearing function at the articulating interface. 
Additionally, the coils are within the operating space of the ball and socket joint and 
are thus vulnerable to damage if primary impingement (contact between the cup and 
stem) occurred. 







































































Figure 5 - Method of packaging showing the location of the recess in the femoral head and positioning 
of the transmission coils [40]. 
Marschener et al [41] developed a system with a custom transponder chip and 
an accelerometer complete with a lock-in amplifier, which filtered out signal noise 
generated by the in-vivo environment. The system also featured onboard storage, that 
could include patient and prosthesis manufacturer data as well as reference data sets 
for loosening trend analysis. The chosen integration solution was to screw the coil and 
electronics housing to the distal end of the prosthesis this ensured vibration coupling 
to the implant and meant that there was no metal surrounding the transponder coil 
[41].  
Sauer et al [42] positioned a sensor system in the femoral head.  The rationale 
for the approach was that firstly, when compared with the manufacturing process of 
stem, modifying the femoral head would be far simpler and cheaper. Secondly, the 
micro-porous surface coating on their stem required a gamma sterilisation process 
that would have a detrimental effect on integrated hardware. Finally, there were less 
femoral head design options compared with the number of stem sizes so using the 
femoral head would reduce the number of required variations. Their system included 
a 3-axis acceleration sensor, lock-in amplifier and inductively coupled data 
transmission and power supply working at 125Hz. The first integration concept was to 
put the sensor system within the cone of a ceramic head, (Figure 6). To secure the 
sensing apparatus a low consistency silicone was selected to provide a durable 
fixation and no electromagnetic disturbance or shielding of the telemetry coils. 
However, it was noted that the titanium acetabular cup would interfere with the 






































































electromagnetic field of the transponder coils and so an alternative approach was 
devised. In this approach, the sensor system was encapsulated within the titanium 
sleeve and the coils, connected by lead throughs, were wound on a polyether ether 
ketone (PEEK) element and mounted on the sleeve (Figure 7). 
 
 Figure 6 - THR sensing system to measure vibration potted in the femoral head [42]. 
 
Figure 7 - THR sensing system to measure vibration showing the sensing system positioned within a 
titanium sleeve and the transponder coil wrapped around a PEEK element [42]. 







































































All three research groups [40]–[42] that investigated telemetric VA were able to 
verify their sensing systems and produced similar vibrational response data to [32]–
[37].  
 
2.2.2 Acoustic Emissions 
Acoustic emission (AE) is the phenomenon of energy release, in the form of acoustic 
(elastic) waves, as a result of a solid material undergoing irreversible changes in its 
internal structure such as crack propagation, phase changes and dislocations within 
the material [43]. The stress waves generated propagate to the materials surface 
(Figure 8) where they can be recorded by sensors, typically piezoelectric. Key 
parameters can then be derived including rise time, maximum signal amplitude, signal 
duration, signal energy and peak counts. If multiple sensors are present the timings of 
the waves arrival at the materials surface can be used to triangulate the point of origin 
and hence the location of the defect.  
 
Figure 8 – Crack propagation in the bone cement will release acoustic waves which will travel to the 
surface of the bone or implant and can then be detected. 
One of the earliest examples of using AE to determine the occurrence of implant 
loosening was conducted in 1989 by Sugiyama et al [44]. They used an AE technique 
to investigate the effect torsional load has on femoral stem loosening and compared 
three cementing techniques including combinations of canal irrigation, manual 
insertion, and vacuum mixing combined with pressure injection. They concluded that 
the most successful cementing technique (as measured by reduced AEs) was 
pressure injection and vacuum mixing of the cement, however some AEs were still 







































































detected suggesting that even the best cementing technique was prone to failure when 
torsional loading was applied [44]. 
Other studies [45]–[47] have also assessed whether AE can be related to 
cement-bone debonding. These studies used a similar approach; placing piezoelectric 
transducers positioned on the surface of, or embedded into, the femoral stem. All 
noted the discontinuous nature of the cumulative AE events and attributed this to the 
propagation of a crack or coalescence between a main crack and a microcrack. 
Additionally, AE waveforms related to cement cracking have higher energy, longer 
signal duration and shorter rise times. Furthermore, work conducted by Rowland et al. 
[48] demonstrated that AE monitoring could be used for the detection of excessive 
wear. They had two AE sensors positioned on the top and bottom fixtures of a five-
station wear rig and noted that one of the stations showed two repeating signals of 
57dB and 66dB amplitude. This was associated with higher volumetric wear and a 
subsequent inspection of the implant components showed evidence of wear that was 
not seen in the other stations. 
Ruther et al [49] developed a novel detection technique they termed magnetic 
oscillator, that uses elements of AE sensing. The sensing process begins with an 
external coil exciting the ferrous head of the oscillator. The oscillator then hits the 
membrane inside the implant and the impulse generated by this contact is dependent 
on the material adjacent to the membrane. For example, close bone contact, indicative 
of successful osseointegration, would mean there would be a lower deformation 
energy and reduced spring dampening. This could be measured by a second external 
detection coil measuring the velocity of the oscillator or by recording the resulting AE 
generated by the oscillator contacting the membrane. A mock-up of how the system 
could be used clinically, a cross section of an instrumented implant and magnified 
views of the oscillator, is shown in Figure 9. 








































































Figure 9 - Mock-up of how the novel magnetic oscillator system could be used clinically, a cross 
section of an instrumented implant and magnified views of the oscillator [29]. 
Ruther et al [50] assessed this concept in an in-vivo rabbit model. Three 
different implant surfaces were used to induce various levels of osseointegration. Over 
the 4 weeks of implantation the AE changed with loosening of the implants (defined 
by the low axial pull-out strength of the implant) showing a continuous increase in 
central frequency. Ruther et al propose a novel solution for a non-destructive in-vivo 
assessment of implant loosening, this required no embedded electronics or telemetry 
systems and has the potential to provide localised measurement of osseointegration. 
However, to cover the full surface of the implant the concept would likely require 
extensive modification to the prosthesis and the addition of the oscillators would 
potentially complicate the manufacturing process.  
 
2.2.3 Eddy Current 
An Eddy current sensor uses a sensing coil supplied with an alternating current to 
create a magnetic field (primary field). If a conductive material intersects the primary 
field, a magnetic field will then be induced within the conductive material (secondary 
field), causing a change in the impedance of the coil. This change in impedance can 
then be detected and related to the distance between the sensing coil and conductive 
material. 







































































Khoke et al [51] examined the efficacy of implanting Eddy current sensors within 
the positioning holes left after total knee arthroplasty with the aim of detecting tibial 
component micromotions. Mohammadbagherpoor et al [52] assessed the use of an 
Eddy current proximity sensor with a 10mm diameter solenoid coil. Their simulated 
and experimental work showed that they were able to detect the micromotions of a 
10mm CoCr rod with a 100µm resolution at a distance of 20mm. Although, an Eddy 
current sensing coil would enable noncontact sensing of micromotions, it remains 
relatively under-developed and there are potential concerns of factors such as sensor 
migration over time with any changes in bone morphology. 
 
2.3 Summary 
Since 1966 less than 100 patients have been reported in literature to have received 
an instrumented hip implant and had in-vivo measurements recorded. Biomechanical 
and thermodynamic measurements, and the assessment of implant fixation have been 
the predominant focus in the field of instrumented hip implants. The first instrumented 
prosthesis to successfully obtain in-vivo measurements was implanted in 1966 (Rydell 
1966). From then to the present there have been several successful attempts at using 
smart hip implants to record measurements in-vivo with the most noteworthy being the 
work conducted by the Orthoload group led by Bergmann. Bergmann’s work improved 
on previous efforts as they were able to measure the 3D load components acting on 
the stem with minimal changes to the external geometry or features of the implant 
components. The packaging of the sensing system within a cavity in the stem meant 
that the components were shielded from the in-vivo environment. However, the 
modifications made to the internal structure to make the hollow shaft (Figure 2b) will 
have involved removal of substantial volumes of material which bring significant risks 
of compromising the integrity of the stem and increased the complexity of the 
manufacturing process. This is likely why the cavity housing the sensing system was 
reduced in the later iterations (Figure 3a & 3b).  
Vibration analysis and tracking the acoustic emissions of the components has 
shown promising results as a method for measuring implant loosening. However, the 
limitations of this technique may be that pre-existing data of a well-fixed implant would 
be required as a reference dataset and that excitation from an external shaker is 






































































required. Although, there could be potential for a far wider range of indications or 
phenomena to be detected from examining the vibration response of an implant 
system for example wear [48]. These techniques are also vulnerable or sensitive to 
background noise from the environment for example generated by an experimental 
hip simulator or when in an in-vivo environment. However, improvements in data 
acquisition and processing techniques and advancements in artificial intelligence and 
machine learning could address these challenges. More recent developments by 
Sauer et al [42] demonstrate that potting a sensor system within the head of the 
implant can address many concerns over sensing performance and implant 
robustness and therefore represent good candidates for clinical use. Furthermore, 
non-ferrous metals are no longer being used for implant components, and so there 
won’t be electromagnetic distortion caused by the acetabular cup disrupting the 
wireless communications. 
   







































































3. Challenges in developing a telemetry system for an instrumented 
hip implant 
The following section will discuss the challenges that need to be overcome to enable 
an effective in-vivo sensing system for use within a THR. These include choice of 
sensor, biocompatibility and integration within the implant, power, communication, and 
regulatory considerations. 
3.1 Choice of Sensor 
The choice of sensor is a key challenge in developing a telemetry system for an 
instrumented implant. The potential sensing applications that have been formulated 
around the common indications for revision surgery of a THR (as shown Figure 1), are 
summarised in Figure 10. The aim being to develop a system that could continuously 
provide useful data on the performance of the implant and occurrence or progression 
of the phenomena associated with the indications for revision surgery.  
Sensor choice is clearly a complex challenge, but most simply should primarily 
be driven by the cause or causes of revision for which data is being collected and 
accordingly the type and complexity of the system required. There are however 
several additional considerations. Firstly, the implant is likely to be in situ and 
functional for over ten years. . So, the information collected upon implantation may 
well be needed to address questions formulated 10-15 years in the future. So 
wherever possible the system needs to be future-proofed. Secondly as more data is 
collected on implant performance it may be that hitherto unknown associations or 
‘surrogate’ measures may be found to link a data output with impending revision. For 
example, could reduction in activity be a pre-cursor to failure caused by loosening? 
Thirdly, the outcomes outlined in Figures 1 and 10 are binary in that they focus 
on revision as an endpoint. It is likely that as more data is collected there will be a 
more nuanced measure of failure such as degradation of activity or reduced range of 
motion. These additional factors may modify the primary driver for sensor choice to 
what sensors or combination of sensors would give the most comprehensive output 
data. 
  







































































Figure 10 – Graphical representations of potential sensing methods within a THR addressing the 
common indications for THR revision surgery 
  







































































3.2 Biocompatibility and integration within the implant 
Integration of sensing system within an IMD such as a total hip replacement has the 
potential to be beneficial however, it is important that the system does not impede the 
normal function of the implant nor cause an adverse biological response. This will 
require miniaturisation of the components to fit the size constraints of the implants as 
well as careful selection of materials and the mounting, embedding or encapsulation 
method. The assessment of biocompatibility should require biological evaluation 
including cytotoxicity testing, examination of the immunological and pathological effect 
on surrounding tissue and characterisation of the expected degradation of the 
implant’s material over the lifetime of the implant as per the recommendations of ISO 
10993 or other such standards. Furthermore, conventional consumer electronics are 
designed for a lifetime of 2 – 5 years whereas the lifetime of an orthopaedic implant is 
longer 10-15 years and so this is a factor that will need to be considered by medical 
device manufacturers (MDMs). 
Typically, electronic components require protection and shielding from dust, 
debris, moisture, temperature and salinity that could interrupt their function or cause a 
degradation in their performance. Electronics implanted in humans must be protected 
from inner body elements such as cells, proteins, platelets, and chemical gases [53]. 
Furthermore, electronic components and the substances for the building up of 
integrated circuits, circuit boards, packaging materials and communication cables are 
not suitable for implantation. Printed circuit boards (PCB) consist predominantly of 
fiberglass and copper foil which are not biocompatible [54], [55], additionally PCB 
manufacture requires toxic chemical treatments.  
Conventional electronics can be used within IMDs but will require encapsulation 
within a polymer or in a hermetically sealed chamber. Low consistency silicone has 
been shown to have favourable water absorption, water solubility and surface 
characteristics for long term implantation when compared to epoxy resin or 
polyurethane [56]. Chambers or recesses can be manufactured within the bulk 
material of the implant be it metal, polymer, glass or ceramic and welded or bonded to 
create a hermetic seal [53]. The hermeticity of the device would need to be assessed 
before medical device approval.  
 







































































3.3 Power delivery system 
Power supply is vital for the telemetry system of an IMD and the selection affects the 
proper function of the circuitry and the longevity of the working system. To date, only 
batteries and inductive power coupling have been used in untethered instrumented 
hip implants. Power supply still remains one of the most limiting factors of IMDs with 
the most significant constraints being size and demands of high capacity/lifespan [53], 
[57].  
 Sensing systems can be classified as active or passive; active systems require 
an internal power supply to drive active components such as a microcontroller unit and 
transducers. Conversely, passive systems don’t receive power internally but instead 
by an external interrogator, whereby, a signal is generated by the interrogator’s 
excitation circuit and sent at radiofrequency to the sensor [58]. A sensing system can 
include active sensors but have a passive power supply unit such as an inductive 
charging link. 
Batteries can supply consistent levels of electrical energy that is stored in the 
form of chemical energy. The first use of a battery within an instrumented hip implant 
was English and Kilvington [59] and then Davy [25]. Many widely accepted IMDs use 
batteries. Examples are drug pumps, cochlear implants and pacemakers which can 
have a lifespan of 8 – 10 years [60]. 
Lithium ion batteries are preferred owing to their high energy density which can 
range from 210 mWh/g to 440 mWh/g [57], [61]. A rechargeable system would satisfy 
the requirements of an IMD including longevity and power supplied. However, during 
the process of recharging battery cells temperature can increase significantly and 
energy capacity is decreased with every recharge cycle. Recharging options are 
limited, one option would be an ultrasonic source. Ultrasonic transcutaneous power 
transfer begins with an external transmitter converting electrical energy into acoustic 
or vibration waves which propagate through the tissue gap to the internal receiver. The 
piezoelectric receiver then converts the acoustic or vibration energy back to electrical 
energy [62]. Awal et al. [63] conducted an empirical review on the use of acoustic 
energy transfer for IMDs and found that the efficiency of such systems can reach an 
efficiency of 45% over a range of 400mm and typically operated over a frequency 
range of 35kHz to 30MHz with a maximum power level being found to be 5.4W. 






































































Although, charging capabilities require additional circuitry [64] thus straining the size 
constraints of IMDs. 
Another option for powering an instrumented hip implant is inductive charging 
which was first used by Carlson et al. [14] an later by other groups [18], [20], [23], [28], 
[40]–[42]. An inductive coupling system has been the preferred method of power 
transfer likely since data can also be transferred inductively.  
 In the early 1830s, Michael Faraday first discovered the concept of 
electromagnetic induction, the theory behind the wireless transfer of electrical energy. 
Inductive power transfer works by passing an alternating current through an “external” 
transmitter coil which generates an electromagnetic field which induces a voltage 
within an “internal” receiver coil [57], [65]. The voltage can then be converted to direct 
current through a voltage rectifier and then be used to power a circuit or charge an 
inbuilt battery or storage capacitor for use at a later time. Factors that can affect 
wireless inductive power efficiency include resonance/operating frequency, distance, 
coil alignment, size and number of turns [65], [66]. Inductive power can satisfy the size 
and energy requirements for an instrumented implant. Theoretically an inductive link 
power system can be used for an infinite amount of time after surgery thus making 
them an attractive option for a long term IMD. However, exposure to high levels of 
electromagnetic fields can be dangerous for patients [64] and if the coils are not 
properly aligned power transfer efficiency is significantly reduced [67]. Wearing the 
transmitter coil system can be uncomfortable for patients, possibly limiting their ability 
to complete activities of daily living and limits the acquisition of data over prolonged 
periods of time [64], [68]. 
A promising alternative technology is the use of energy harvesting to convert 
the mechanical energy from joint motion into electrical energy for powering implants. 
The concern is whether the joints low frequency movement (typically <1Hz whilst 
walking) would be sufficient to generate the required power. Unlike conventional 
sources of mechanical energy, movements can be infrequent and inconsistent and so 
traditional power management and battery charging systems will be unsuitable. Silva 
et al. [69] developed a hip prosthesis with three separate power generators including 
a translation and rotation based electromagnetic generator and a piezoelectric 
generator powered by a ceramic diaphragm located in the hollow femoral head, shown 






































































in Figure 11. Each generator had an individual power conditioning circuit that fed into 
the main ultracapacitor energy reservoir, so the implant could function once the 
generators begin to produce enough energy, or the energy can be stored. Once a 
predetermined voltage had been reached within the ultracapacitor the energy stored 
within was delivered to the IMDs telemetry circuit. Other attempts at developing energy 
harvesting systems for a THR have similarly used a linear electromagnetic generator 
[70] and piezoelectric transducers [71]. 
 
 
Figure 11 – Hip prosthesis with three independent power generating systems [69] 
 
3.4 Data transfer system 
Wireless communication would be a necessity for the telemetry system of an 
implantable medical device, particularly in a deeply implanted orthopaedic implant. 
Wired communications were used in the first iterations of instrumented implants but 
are not a viable option as they would induce unnecessary pain or discomfort to the 
patient and pose an infection risk. A wireless connection would also better enable 
continuous data collection without causing inconvenience to patients. In which case 







































































designers will have to consider data transfer rate, range, permittivity through human 
tissue and the additional size and power consumption constraints. 
 The choice of the wireless communication system will depend on what data 
needs to be transferred to or from the implant, and when. If the system’s output only 
involves small amounts of data (e.g. ID of the patient and implant or single 
measurement of blood glucose or temperature) or if the frequency of measurement is 
low (e.g. 1 sample per hour) this places lower demands on a real time data transfer 
system. Similarly, if the collected data can be stored or processed locally (in the 
implant), it can be uploaded at the convenience of the user, without requiring a 
continuous telemetry system in place. One such low capacity yet versatile data 
transfer method could be radio frequency identification (RFID), which is being seen in 
warehouse inventory tracking, pet identification, contactless payments and tracking 
marathon runner times. 
A RFID system consists of a transponder or tag, a reader or interrogator, 
accompanying antennas to enable communication through radio frequency and 
software that controls the system and manages the data [72]. The tags will have a chip 
that stores the identification data or electronic product code (EPC). Tags can be active, 
powered by a battery and favoured for their increased range, or passive, powered by 
the reader’s signal and favoured for their low cost (<10 cents) [73].  
RFID technology is used to track items and store low levels of data so, could 
be used to identify medical devices once they have been implanted and include data 
on the make and model of the implant, reasons for the intervention, the surgeon who 
completed the procedure and details of the surgical approach. One such company 
addressing this is Ortho-tag in collaboration with the University of Pittsburgh. Ortho-
tag was developed to provide a non-invasive, battery less and wireless method of 
identifying an implanted orthopaedic device. The system consists of a RFID chip 
embedded within an implantable tag and a ‘touch probe’ that uses transcutaneous 
near field communication to power and communicate with the tag from outside the 
body [74]. Orthotag claim their system is capable of storing information on an 
implanted medical device, information which could include X-rays and patient medical 
records [75]. 







































































An enhancement to a RFID system, that could be beneficial in orthopaedic 
devices, is passive or battery-less sensing capabilities, such systems are known as 
computational RFIDs (CRFID) [73]. Sample et al. [76] achieved this with their wireless 
identification and sensing platform (WISP) which could both receive power and 
communicate data to a wireless RFID reader. They showed the efficacy of their WISP 
by integrating sensors such as temperature, ambient light, rectified voltage, and 
orientation. Other groups have looked at the possibility of using CRFID systems within 
IMDs including pressure sensors for orthopaedic implants [77] and blood glucose 
sensors for continuous blood glucose monitoring [78]. Ortho-tag suggest that their 
system can feature sensors for the in-vivo measurement of pH and temperature to 
indicate infection in the tissue surrounding an implant [75]. 
However, past in-vivo sensing systems have been used to record real time load 
and vibration data at frequencies >1Hz which required data transfer systems with 
higher data transfer rates. The predominant method used in the majority of past 
instrumented hip implants has been inductive data transfer with [28], [40]–[42] all using 
inductive coupling data transfer and Bergmann [28] having a combined power and 
data coil. Nikola Tesla was the first to realise that electrical energy, and so data, could 
be transmitted wirelessly between two inductively resonant coils [79]. Inductive power 
transfer can reach a data transfer rate of up to 100 Mbps at a range of 6cm outside 
the body [80]. However, as well as the aforementioned limitations of using inductive 
coupling for power transfer, when being used for data transfer an inductively coupled 
system is susceptible to interference from nearby electromagnetic fields [53], [80].  
These limitations lead many medical device companies to use, antenna based, 
radio frequency (RF) transceivers for wireless communications between an IMD and 
external unit. The IMD is equipped with an antenna that when fed with a signal radiates 
electromagnetic waves through the body to an external receiver [81]. The radio 
frequency spectrum ranges from 3KHz to 300GHz; between 30MHz and 400MHz is 
the human body’s resonance range where specific absorption rate is at its highest [82] 
meaning that RF waves can penetrate the furthest into the body. Therefore, a 
transceiver operating around this frequency range would be desirable for a deeply 
implanted medical device. 







































































In 1999, the increased use of RF systems in IMDs lead the Federal 
Communications Commission (FCC) standardising the Medical Implant 
Communication Service (MICS), to the RF band 402 – 405 MHz. In 2009 the FCC 
upgraded the MICS to the Medradio service which included two additional “wing 
bands” thus extending the band to 401 – 406 MHz [80], [81], [83]. Global medical 
device companies have manufactured their own remote monitoring systems using 
MICS: Biotronik Home Monitoring® (FDA approval 2001), Medtronic Carelink® 
Network (FDA approval 2005) and Merlin.net® Patient Care Network (FDA approval 
2007) [84].  
Another option for wireless communication is Bluetooth or Bluetooth low energy 
(BLE). Bluetooth is a standard for wireless exchange of data operating at a radio 
frequency of 2.45GHz. At this frequency the radio waves will have a penetration depth 
of approx. <4cm in fat and <2cm in skin and muscle [85], [86] however, the higher 
frequency means that BLE has a far higher data transfer rate, up to 2Mbps [87].  
To date Bluetooth has not been used in an instrumented hip implant but has 
seen use in other IMDs. The Confirm Rx ICM (Abbott, Ill, US) is the first Bluetooth 
enabled and smartphone compatible implantable cardiac monitor to have received 
FDA approval in Oct 2017 [88]. In July 2018 the world’s first pacemaker with Bluetooth 
technology (Azure Bluesync pacemaker, Medtronic, Db, Ireland) was implanted [89]. 
Bluetooth is widely used within consumer electronics with many personal devices 
being Bluetooth enabled. Based on the early adoption of Bluetooth enabled IMDs it is 
reasonable to assume that devices of a similar nature will become more widespread 
throughout the medical sector. However, for application within the hip joint the low 
penetration of 2.4GHz RF waves will make Bluetooth an unfeasible option. An 
alternate solution to this is a dual band radio repeater that can receive radio signals at 
one frequency and retransmit at another. Kiourti et al. [90] configured an on-body 
antenna to receive transmissions from an IMD in the MedRadio band 401 – 406 MHz 
and retransmit the received data to an external device in the ISM band, 2400 – 2480 
MHz. This approach would also improve energy efficiency as transmitting low 
frequency waves is far more energy efficient therefore reducing the power 
consumption of the IMD’s telemetry system.  
 






































































3.5 Regulatory considerations – Medical device approval 
Europe and the US are the largest global markets for medical devices. To market their 
devices within these territories MDMs need to comply with the regulations laid out by 
the European Commission in their Medical Devices Regulation (MDR) to achieve a 
CE mark or be approved by the U.S. Food and Drug Administration (FDA), 
respectively.  
An in-vivo sensing system for use within a THR will be a class III (implanted) 
medical device and so will require extensive pre-clinical and clinical testing to provide 
evidence of its efficacy and safety before it can be approved. The same will be required 
when following the FDA’s pre-market approval (PMA) pathway for new medical 
devices when entering the US market.  
If integration of the telemetry system has required modification of the implant, 
then new approval will be required for the implant. If a pre-existing implant has been 
used, then the FDA’s 510(k) pathway would provide a shorter route to approval. 
Nevertheless, these additional regulatory hurdles will mean further costs, risks and 
inconvenience for the MDM. Whereas, if the sensing system is able to integrate with 
the implant without changing function or geometry then approval requirements may be 
more easily met. Furthermore, the safety of the in-vivo sensing system, and 
accompanying telemetry, should not be considered in isolation and interactions with 
the implant should also be considered. Attaching or embedding the sensing system 
could lead to corrosion, generation of wear particles and there is the risk that the 
system will move from the intended position or become separated from the implant. 
These implications should also be considered for the entire lifetime of the implant even 
if the telemetry system becomes inactive or stops working. 
In a 2018 FDA public workshop [8] it was highlighted that care should be taken 
to go beyond physical characteristics associated with pre-clinical testing, such as 
biocompatibility, sterilisation, electrical and mechanical performance, and sensor 
accuracy and repeatability. For in-vivo sensing systems, regulatory considerations 
should also encompass validation of the metrics produced and the level of evidence 
required should be dependent on how the data will be used, for example if the sensor 
is delivering a treatment or providing a diagnosis of a potentially life-threatening 







































































condition. In either scenario the wrong result would cause harm to the patient or be 
life threatening.  
 
3.6 Regulatory considerations - Cybersecurity 
In 2017, the global WannaCry cyber-attack was estimated to have cost the NHS £92m, 
£19m lost output and £73m in IT costs the majority being spent in the aftermath [91]. 
A study conducted by Clearswift revealed that in the UK, 67% of healthcare 
organisations suffered a cybersecurity incident in 2019 [92]. The risk of cybersecurity 
related incidents within healthcare are increasing as more medical devices have 
wireless connectivity and are joining the internet of things.  
In the past there was concern over malicious cyberhackers gaining unlawful 
access to a patient’s implanted medical device (IMD) and causing harm to the patient. 
In a 2013 interview, Former Vice President Dick Cheney revealed that in 2007 he had 
the wireless connectivity of his pacemaker disabled to avoid the possibility of an 
assassination attempt [93]. Halperin et al. [94] were the first research group to show 
that an IMD could be infiltrated and patient data and safety put at risk. In 2011, amateur 
hacker Barnaby Jack demonstrated live on stage, at the Hacker Halted conference in 
Miami, how he could hack into an insulin pump and deliver a fatal dose to the user 
[95], [96]. The following year Jack performed a similar live demonstration in which he 
hacked into a pacemaker and commanded the device to deliver a deadly voltage surge 
of 830V [96], [97]. Although theoretically possible it is highly unlikely that attacks like 
these would ever occur. Dick Cheney’s unique public figure status meant that he was 
at a high risk and so every precaution was taken to guard him against possible attacks. 
Additionally, hacking into a user’s pacemaker would require the attacker holding 
‘suspicious’ specialised electronic equipment close to the user for an extended period 
of time therefore making it hard for the attack process to be scaled and in general 
there are far easier, more effective and profitable ways to cause harm or steal a 
person’s data [98]. To-date there is no evidence of cases where a patient’s IMD has 
been hacked with malicious intent. Though there have been device recalls [99], [100] 
and safety communications issued by the FDA [101]–[104] where cybersecurity 
vulnerabilities were cited.  






































































Cardiac and drug delivery devices, such as pacemakers and insulin pumps, 
carry higher levels of risk whereas, a non-active in-vivo sensing system will carry less 
risk as it only provides diagnostic capabilities so cannot have a ‘physical effect’ on the 
patient or user. However, if a smart implant capable of in-vivo sensing is realised, and 
intended to be used clinically, it is likely that the device would include or even require 
functionality to store data on the patient and their medical history. This data could be 
a potential target for malicious cyber hackers as medical records are worth more than 
a credit card number or bank details when sold on the dark web [105], [106]. Although 
there will be an inherent risk of an IMD being hacked, this is not the only component 
of cybersecurity that should concern MDMs and regulatory bodies instead, the majority 
of medical device cybersecurity should be preventing accidental cyber harm and, 
making sure the system is robust to the unknown and unexpected [107].  
In 2013, the FDA released a safety communication that warned MDMs, 
hospitals and users that cybersecurity breaches could affect the proper function of an 
IMD [108]. Building upon this the FDA issued the “Content of Premarket Submissions 
for Management of Cybersecurity in Medical Devices” guidance document [109], and 
updated in 2018 [110]. The guidance encourages MDMs to consider cybersecurity 
measures during the entire lifecycle of the device and provides details on the 
documentation required for the PMA submission with regards to cybersecurity. 
Additionally, in 2019, the Medical Device Coordination Group (MDCG) released 
“Guidance on Cybersecurity for medical devices” [111] which provides 
recommendations to MDMs on how to satisfy the requirements laid out in the MDD 
that relate to cybersecurity.  








































































The number of total hip replacements are increasing, complication and revision rates 
whilst low are still at undesirable levels. An in-vivo sensing system with telemetric 
capabilities would be beneficial as a means of gathering valuable data on the implant’s 
function and the condition of the surrounding tissue. This data could be used to verify 
in-silico and in-vitro studies, inform improvements in implant design and surgical 
technique, and guide postoperative care. If real time condition monitoring is achieved 
along with intelligent recognition of adverse events and deviations from a patient’s 
normal function, then such systems could provide advantages including remote patient 
monitoring, improved accessibility to healthcare and continuous as oppose to episodic 
and largely unnecessary assessment and early detect of problems. 
Since the implantation of the first instrumented hip implant in the 1960s less 
than 100 patients have received an instrumented implant capable of in-vivo sensing. 
These implants have measured biomechanical metrics, including force and moments 
and temperature. The data gathered has helped progress understanding of how a THR 
functions in-vivo and so informed improvements in implant design and surgical 
technique. However, force, moments and temperature measurements are currently 
not sufficient to deduce early indications for revision surgery. However, they are 
important metrics and may still be required in a sensing system for use in a smart THR 
capable of condition monitoring and intelligent feature recognition. Other experimental 
work has looked at measuring levels of implant loosening presumably because 
loosening is the most common indication for revision surgery in THR and indeed other 
orthopaedic implants. This work has shown potential but until it can be shown that the 
diagnostic accuracy and reliability is matched to standard radiographic methods then, 
clinical translation will not be a possibility. 
Widespread adoption of smart instrumented THRs and IMDs will not be realised 
until several key challenges have been overcome these include: what sensing method 
is used, biocompatibility and integration within the implant, power delivery, 
communication, and regulatory considerations. Additionally, product liability is also a 
limiting factor within the field of IMDs as MDMs will not want to take on the additional 
risks associated with developing and marketing such technology without measurable 
benefits either in improved outcomes or reduced costs but also to the wider healthcare 
system. Also, the expected lifetime of a THR is >15 years whereas the lifetime of 






































































common consumer electronics such as a smartphone is <5 years (whilst also receiving 
regular software updates). This will need to be considered by MDMs when designing 
the hardware and software of the IMD. Smart implantable medical devices, such as 
pacemakers and insulin pumps, are becoming more accepted and widely used as 
clinical interventions. Furthermore, advances in technology such as wireless power 
and telemetry systems, suggests that the development and eventual adoption of an 
instrumented hip implant, capable of real time condition monitoring, is imminent.  
The successful introduction of technology outlined in this review would not only 
benefit the patient, but it would also enable clinicians to base decisions on more 
objective quantitative data This would potentially obviate the need for follow-up clinics 
for all patients thereby reducing hospital workload and hence costs which would 
benefit the payer whether they are a government or an insurance company.  
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